Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Cytarabine 10venetoclax 8Rituximab 7Daunorubicin 7nilotinib 6Azacitidine 6blinatumomab 5Bendamustine Hydrochloride 5bosutinib 4Imatinib Mesylate 4obinutuzumab 3asciminib 3acalabrutinib 3Mitoxantrone 3Methotrexate 3Etoposide 3Dexamethasone 3Decitabine 3Dasatinib 3zanubrutinib 2trametinib 2talquetamab 2revumenib 2pirtobrutinib 2pegaspargase 2ivosidenib 2idelalisib 2ibrutinib 2fludarabine 2decitabine and cedazuridine drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Idarubicin × Other hematologic neoplasm × Clear all
NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Astellas Pharma Inc

Phase 3 Completed
371 enrolled 36 charts 2 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

Daiichi Sankyo

Phase 3 Completed
539 enrolled 20 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡